Filing Details

Accession Number:
0001437749-21-023466
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-07 21:26:02
Reporting Period:
2021-10-05
Accepted Time:
2021-10-07 21:26:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
834365 Biolife Solutions Inc BLFS Electromedical & Electrotherapeutic Apparatus (3845) 943076866
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1389512 Michael Rice C/O Biolife Solutions, Inc.
3303 Monte Villa Parkway, Suite 310
Bothell WA 98021
Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-10-05 11,461 $1.64 276,016 No 4 M Direct
Common Stock Disposition 2021-10-05 11,461 $40.63 264,555 No 4 S Direct
Common Stock Acquisiton 2021-10-07 11,461 $1.64 276,016 No 4 M Direct
Common Stock Disposition 2021-10-07 11,461 $40.55 264,555 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option Disposition 2021-10-05 11,461 $0.00 11,461 $1.64
Common Stock Employee Stock Option Disposition 2021-10-07 11,461 $0.00 11,461 $1.64
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
57,308 2021-12-20 No 4 M Direct
45,847 2021-12-20 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $41.08, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.81 to $40.92, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019.